ALX Oncology Holdings Inc.

NasdaqGS:ALXO 주식 보고서

시가총액: US$314.2m

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ALX Oncology Holdings 관리

관리 기준 확인 2/4

ALX Oncology Holdings' CEO는 Jason Lettmann, Sep2023 에 임명되었습니다 의 임기는 1년 미만입니다. 총 연간 보상은 $ 5.32M, 4.1% 로 구성됩니다. 4.1% 급여 및 95.9% 보너스(회사 주식 및 옵션 포함). 는 $ 773.52K 가치에 해당하는 회사 주식의 0.21% 직접 소유합니다. 773.52K. 경영진과 이사회의 평균 재임 기간은 각각 2.8 년과 3.7 년입니다.

주요 정보

Jason Lettmann

최고 경영자

US$5.3m

총 보상

CEO 급여 비율4.1%
CEO 임기less than a year
CEO 소유권0.2%
경영진 평균 재임 기간2.8yrs
이사회 평균 재임 기간3.7yrs

최근 관리 업데이트

Recent updates

ALX Oncology: Finally Reaching A Reasonable Buy-In Valuation

Jun 27

ALX Oncology: Trying To Justify The Hype

Apr 18

Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

Mar 12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?

ALX Oncology GAAP EPS of -$0.81 misses by $0.18

Aug 08

ALX Oncology stock rises on FDA fast track status for evorpacept to treat head/neck cancer

Aug 01

ALX Oncology stock rises 14% on evorpacept's FDA orphan drug status for blood cancer

Jun 29

ALX Oncology Is Turning Into An Also-Ran In Anti-CD47

Feb 15

ALX Oncology Stock: Attractive After Recent Data And Slump In Price

Nov 30

ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space

Sep 08

Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Jul 08
Here's Why We're Not Too Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Situation

Dosing underway in ALX Oncology's ALX148 combo study in head and neck cancer

May 10

We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Mar 25
We're Not Very Worried About ALX Oncology Holdings' (NASDAQ:ALXO) Cash Burn Rate

Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

Feb 01
Here's What ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) Shareholder Ownership Structure Looks Like

ALX Oncology: All Their Eggs In The Proverbial Basket

Jan 07

ALX Oncology (ALXO) Presents At 62nd Virtual Annual Meeting of ASH - Slideshow

Dec 11

ALX Oncology prices upsized stock offering at $76

Dec 10

ALX Oncology announces proposed public offering

Dec 07

ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow

Nov 20

ALX Oncology reports Q3 results

Nov 12

Dosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study

Oct 28

CEO 보상 분석

Jason Lettmann 의 보수는 ALX Oncology Holdings 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Mar 31 2024n/an/a

-US$166m

Dec 31 2023US$5mUS$217k

-US$161m

Sep 30 2023n/an/a

-US$146m

Jun 30 2023n/an/a

-US$130m

Mar 31 2023n/an/a

-US$129m

Dec 31 2022US$116kn/a

-US$123m

Sep 30 2022n/an/a

-US$121m

Jun 30 2022n/an/a

-US$110m

Mar 31 2022n/an/a

-US$94m

Dec 31 2021US$537kn/a

-US$83m

Sep 30 2021n/an/a

-US$74m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$58m

Dec 31 2020US$352kn/a

-US$51m

보상 대 시장: Jason 의 총 보상 ($USD 5.32M )은 US 시장( $USD 2.46M ).

보상과 수익: 회사가 수익성이 없는 동안 Jason 의 보상이 증가했습니다.

CEO

Jason Lettmann (47 yo)

less than a year

테뉴어

US$5,320,096

보상

Mr. Jason W. Lettmann had been an Independent Director of ALX Oncology Holdings Inc. since April 2020 until September 6, 2023 and previously served as a Director from March 2015 to May 2017 also serves as...

리더십 팀

이름위치테뉴어보상소유권
Corey Goodman
Executive Chairman9.3yrsUS$206.61k0.32%
$ 1.0m
Jason Lettmann
CEO & Directorless than a yearUS$5.32m0.21%
$ 673.1k
Jaume Pons
Founder9.2yrsUS$2.75m0.86%
$ 2.7m
Peter Garcia
Chief Financial Officer4.4yrsUS$1.30m0.098%
$ 308.9k
Sophia Randolph
Chief Medical Officer & Director8yrsUS$1.37m0.47%
$ 1.5m
Michael Chang
Vice President of Operationsno data데이터 없음데이터 없음
Shelly Pinto
Senior VP of Finance & Chief Accounting Officer3.1yrsUS$7.23m0.046%
$ 144.5k
Caitlyn Doherty
Manager of Investor Relations & Corporate Communicationsno data데이터 없음데이터 없음
Christopher Byrd
General Counsel2.1yrs데이터 없음데이터 없음
Athanasios Tsiatis
Senior Vice President of Clinical Development2.6yrs데이터 없음데이터 없음
Lin Yeong-Liang
Senior Vice President of Drug Safety & Pharmacovigilance2yrs데이터 없음데이터 없음
Lisa Sauer
Senior Vice President of Regulatory Affairs & Quality Assuranceless than a year데이터 없음데이터 없음

2.8yrs

평균 재임 기간

57yo

평균 연령

경험이 풍부한 관리: ALXO 의 관리팀은 경험 ( 2.8 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Corey Goodman
Executive Chairman9.3yrsUS$206.61k0.32%
$ 1.0m
Jason Lettmann
CEO & Director4.2yrsUS$5.32m0.21%
$ 673.1k
Jaume Pons
Founder9.2yrsUS$2.75m0.86%
$ 2.7m
Sophia Randolph
Chief Medical Officer & Director3.3yrsUS$1.37m0.47%
$ 1.5m
Keith Flaherty
Chair of the Scientific Advisory Board3.7yrs데이터 없음데이터 없음
Scott Garland
Independent Director1.6yrsUS$105.66k0%
$ 0
Charles Baum
Member of the Scientific Advisory Board3.7yrs데이터 없음데이터 없음
Rehka Hemrajani
Independent Director4.2yrsUS$181.02k0.0058%
$ 18.1k
Kipp Weiskopf
Member of the Scientific Advisory Board3.7yrs데이터 없음데이터 없음

3.7yrs

평균 재임 기간

55.5yo

평균 연령

경험이 풍부한 이사회: ALXO 의 이사회는 경험(평균 재직 기간 3.7 년)으로 간주됩니다.